Esperion Says FDA Stance Means No Clear Regulatory Path For ETC-1002
Esperion Therapeutics and the FDA have failed to reach agreement on a definitive approval path for the company's cholesterol drug ETC-1002, raising the possibility of a long and more expensive development pathway for the oral therapy.
You may also be interested in...
Amgen's FOURIER outcomes study of Repatha supports LDL-lowering in high risk patients, but price may have to come down dramatically to spur wide use of the PCSK9 inhibitors with the subjective condition of statin intolerance.
Worries Esperion Therapeutics is falling behind competitors in the race to bring the next generation of powerful cholesterol-lowering drug to market suddenly surfaced this week, sending the US biotech's share price plummeting more than 40% on Tuesday.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.